Transgene Stock

Transgene EBITDA per Employee

The EBITDA per Employee of Transgene (TNG.PA) as of Aug 3, 2026 is -215,735.85 EUR. In the previous year, EBITDA per Employee was -178,779.87 EUR — a change of 20.67% (lower).

EBITDA per Employee

-215,735.85EUR

YoY

20.67%

Last updated:

EBITDA per Employee of Transgene is 2026 -215,735.85 EUR. EBITDA per Employee of Transgene was 2025 -178,779.87 EUR. It decreases by 20.67% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

EBITDA per Employee of Transgene is -215,735.85 EUR in 2026.

EBITDA per Employee of Transgene changed from -178,779.87 EUR to -215,735.85 EUR, representing a 20.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Transgene since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Transgene historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Workforce — Transgene

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Transgene